Pressure BioSciences, Inc. (PBIO: OTCQB) | Pressure

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pressure BioSciences, Inc. (PBIO: OTCQB) | Pressure BioSciences, Inc. Reports Continued Strong Sales Growth Pressure BioSciences, Inc. Reports Continued Strong Sales Growth

Pressure BioSciences, Inc. Reports Continued Strong Sales Growth

Products and Services Revenue Up 82%, Consumables Revenue Up 101% in First Quarter 2014

Investor Conference Call Slated for Thursday, May 15th at 4:30 PM EDT

PR Newswire

SOUTH EASTON, Mass. , May 15, 2014 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced financial results for the three-month period ended March 31, 2014 and provided a business update.

Total revenue for the first quarter of 2014 was $404,147 compared to $370,737 for the same period in 2013, a 9% increase. Revenue from the sale of products and services was $404,147 for Q1 2014 compared to $221,569 for the same period in 2013, an increase of 82%.  Grant revenue in Q1 2014 was $0 compared to $149,168 for the same period in the prior year.  Sales of consumables were $54,612 for the three months ended March 31, 2014 compared to $27,224 for the same period in 2013, an increase of 101%.

Operating loss for the first quarter of 2014 was $782,366 compared to $725,024 for the same period in 2013, an increase of 8%.  Contributing to this increase in operating loss was the lack of grant revenue in the first quarter of 2014, which negatively impacted gross margins.  Work on government grants is typically performed by the Company's research and development staff and their cost is recorded as R&D with little incremental direct costs charged to cost of sales.  Operating expenses in Q1 2014 were consistent with 2013 levels.

Loss per common share (basic and diluted) was $0.25 for the 2014 first quarter compared to $0.11 for the same period in 2013.  The additional loss per common share was due primarily to the change in the fair value of derivative instruments in Q1 2014 and a deemed dividend on our convertible preferred stock.

Richard P. Thomley , Chief Financial Officer of PBI, said: "Despite having no grant revenue in the first quarter of 2014 (compared to $149,168 in the same quarter of 2013), total revenue still increased by $33,410 or 9%.  Products and services revenue showed a substantive sequential quarterly increase in Q1 2014 over Q1 2013, posting a gain of 82%. This was aided by a 101% increase in consumables revenue. It is important to note that we achieved these results while keeping operating expenses close to 2013 levels. We believe our Q1 2014 financial performance reflects continued, measurable progress in our stated goal of developing a sound financial roadmap for PBI moving forward."

Mr. Richard T. Schumacher , President and CEO of PBI, commented: "In addition to the strong financial results reported for the 2014 first quarter, we achieved several other notable successes, including:

  • The closing of two tranches ( $1.8M ) of our Series K PIPE (initial goal $1.5M ) to supplement the $1M we had already raised in December 2013 .
  • The release of our ultra-high pressure HUB880 instrument to the market as scheduled (Q1 2014).
  • Continued progress on the development of our game-changing, high-throughput ("HT"), pressure cycling technology ("PCT")-based Platform.  We remain on target to release this new PCT System as planned at the annual meeting of the American Society for Mass Spectrometry in mid-June 2014 ."

Mr. Schumacher continued: "We believe 2014 revenue will continue to increase, and for the year will exceed our record revenue of 2013.  We believe this revenue ramp will be driven by sales from both existing and new products (instruments and consumables), from our expanding network of international distributors, and from grants currently being reviewed.  We also believe that the release of the new HT PCT-based Platform next month will help foster discussions with large, multi-national sales, marketing, and distribution partners, and that these discussions will lead to at least one major strategic partnership before years' end.  For all of these reasons and more, we believe there has never been a better time to be a stakeholder in PBIO."

Earnings Call
The Company will hold an Earnings Conference Call at 4:30 PM EDT on Thursday, May 15 , 2014.  To attend this teleconference via telephone: Dial-in: (877) 407-8031 ( North America ); (201) 689-8031 (International). Verbal Passcode (to be given to the operator): PBI First Quarter 2014 Financial Conference Call.

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery, drug discovery & design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.    

Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward looking-statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. The Company's financial results for the quarter ended March 31, 2014 may not necessarily be indicative of future results. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2013 , and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following link: 
http://www.pressurebiosciences.com  
Please visit us on Facebook, LinkedIn, and Twitter.

 

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(UNAUDITED)










For the Three Months Ended





March 31,





2014


2013








Revenue:






Products, services, other


$404,147


$221,569


Grant revenue


-


149,168



Total revenue


404,147


370,737








Costs and expenses:






Cost of products, services and grants


177,606


104,544


Research and development


231,088


246,458


Selling and marketing


171,340


193,900


General and administrative


606,479


550,859



Total operating costs and expenses


1,186,513


1,095,761










Operating loss


(782,366)


(725,024)








Other (expense) income:






Interest (expense) income, net


(244,612)


(8,900)


Change in fair value of derivative liabilities


(732,677)


(45,445)



Total other (expense) income


(977,289)


(54,345)









Net loss


(1,759,655)


(779,369)


Accrued dividend on convertible preferred stock


(44,987)


(32,173)


Deemed dividend on convertible preferred stock


(1,280,066)


(582,548)


Net loss applicable to common shareholders


$(3,084,708)


$(1,394,090)
















Net loss per share attributable to common stockholders - basic and diluted

$(0.25)


$(0.11)









Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation


12,122,045


12,149,267

 

 

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS







March 31,


December 31,

ASSETS

2014

(Unaudited)


2013

(Audited)

CURRENT ASSETS





Cash and cash equivalents

$428,537


$31,417


Accounts receivable

178,362


147,635


Inventories, net of $50,000 reserve at March 31, 2014 and December 31, 2013

786,752


736,676


Prepaid income taxes

7,381


7,381


Prepaid expenses and other current assets

228,972


85,573


Total current assets

1,630,004


1,008,682

Property and  equipment, net

55,714


58,102


Intangible assets, net

24,340


36,498

TOTAL ASSETS

$1,710,058


$1,103,282


LIABILITIES AND STOCKHOLDERS' DEFICIT




CURRENT LIABILITIES





Accounts payable

$1,012,785


$1,102,772


Accrued employee compensation

131,351


149,333


Accrued professional fees and other

569,270


615,244


Deferred revenue

23,774


28,189


Promissory note

-


75,000


Related party debt

5,249


25,182


Convertible debt, net of debt discount of $201,275 at March 31, 2014 and $331,806 at Dec. 31, 2013

171,727


281,796


Other debt

55,294


89,989


Warrant derivative liability

585,281


344,570


Conversion option liability

393,519


356,197


Total current liabilities

2,948,250


3,068,272

LONG TERM LIABILITIES





Deferred revenue

2,785


2,785

TOTAL LIABILITIES

2,951,035


3,071,057

STOCKHOLDERS' DEFICIT





Series D convertible preferred stock, $.01 par value; 850 shares authorized;

300 shares issued and outstanding on March 31, 2014 and on Dec. 31, 2013

3


3


Series G convertible preferred stock, $.01 par value; 240,000 shares authorized;

145,320 shares issued and outstanding on March 31, 2014 and on Dec. 31, 2013

1,453


1,453


Series H convertible preferred stock, $.01 par value; 10,000 shares authorized,

10,000 shares issued and outstanding on March 31, 2014 and on Dec. 31, 2013

100


100


Series J convertible preferred stock, $.01 par value; 6,250 shares authorized;

5,088 shares issued and outstanding on March 31, 2014 and on Dec. 31, 2013

51


51


Series K convertible preferred stock, $.01 par value; 15,000 shares authorized;

10,729 shares issued and outstanding on March 31, 2014 and 4,000 on Dec. 31, 2013

107


40


Common stock, $.01 par value; 50,000,000 shares authorized; 12,624,267 and

12,024,267 shares issued and outstanding on March 31, 2014 and on Dec. 31, 2013,

respectively

126,243


120,243


Warrants to acquire preferred stock and common stock

4,856,876


4,267,402


Additional paid-in capital

22,725,887


19,509,921


Accumulated deficit

(28,951,697)


(25,866,988)


Total stockholders' deficit

(1,240,977)


(1,967,775)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT

$1,710,058


$1,103,282

 

Investor Contacts:
Richard T. Schumacher , President & CEO, Pressure BioSciences, Inc. (508) 230-1828 (T)
Richard P. Thomley , Chief Financial Officer, Pressure BioSciences, Inc. (508) 230-1828 (T)
Howard Gostfrand , President, American Capital Ventures (858) 568-7059 (T)

SOURCE Pressure BioSciences, Inc.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Adcendo’s Early Sarcoma Data Earns a Careful Look

Updated Category News Views 22

Sarcoma data rarely gives anyone permission to pound the table, yet Adcendo’s first look at ADCE-D01 deserves more than a polite nod. In advanced soft tissue sarcoma, where patients have often run through the usual options and second-line response rates historically sit around 4% to 10%, a reported 30% objective response rate on the every-two-week schedule is...

Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens

Updated Category News Views 90

Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...

Continue Reading
GFT's Banking Leader Tag Puts Execution Risks Into Focus

Updated Category News Views 39

A banking overhaul is where glossy slides go to die. That is why GFT Technologies being named a Leader in QKS Group's 2026 SPARK Matrix for Digital Banking Services deserves a little more attention than the usual analyst-firm trumpet blast. This is not a prize for making a pretty mobile app. The work described here runs through strategy, architecture, core-platform...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 51

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading
American Pride Bank Tests a Fast Southeast Expansion

Updated Category News Views 197

Those old Winston-Salem smokestacks make a fitting backdrop for a bank trying to build something new, and American Pride Bank is moving with uncommon speed. Its new office at 450 N. Patterson Ave., Suite 200 sits in the Bailey South building in Innovation Quarter, across from Bailey Park and amid a district deliberately remade for founders, researchers and growing...

Continue Reading
Housing's Value Equation Is Getting More Complicated

Updated Category News Views 100

A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 60

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
EmTech AI 2027 Puts AI Ambitions Through Reality Test

Updated Category News Views 21

A three-day gathering cannot settle AI's biggest arguments, but MIT Technology Review has picked the right fight for EmTech AI 2027: make the industry face a Reality Test. The conference runs May 11–13, 2027, at MIT's campus and online, and that theme lands because the AI conversation has spent plenty of time admiring the engine while skipping the ugly maintenance bill....

Continue Reading
Miami I20 Tests Appetite for Long-Term U.S. Capital

Updated Category News Views 194

Five days in a Miami airport hotel may not sound like the machinery of national investment policy, yet the guest list for the inaugural I20 Summit is serious enough to make capital markets sit up. From December 11 through 15, the Sovereign Wealth Fund Institute plans to bring sovereign funds, pensions, endowments, family offices, business leaders and U.S....

Continue Reading
Yunnan Tin’s AI Materials Push Has Real Operating Teeth

Updated Category News Views 13

Tin rarely gets the spotlight until the machinery behind modern computing starts demanding more of it. Yunnan Tin Group is making the sensible case that this unglamorous metal can matter a great deal in semiconductors, artificial intelligence infrastructure and new-energy hardware. There is plenty of corporate ambition wrapped around that case, naturally, but a few...

Continue Reading

Top 5 Most Recently Viewed Articles

AXIA Time Launches New College Football Playoff Limited Edition

Updated Category News Views 81

Introducing AXIA Time's New College Football Playoff Collection AXIA Time is making waves with its expanded partnership with the College Football Playoff (CFP) and the launch of a fantastic new collection. Known for its high-quality craftsmanship, AXIA Time has introduced a series of limited edition, heirloom-quality watches specifically created for the 2025 College...

Continue Reading
Uphold Launches Staking Services for UK Users Amid Changes

Updated Category News Views 375

Uphold Introduces Staking Features for UK Customers Customers of Uphold can now take advantage of staking rewards on their crypto assets. This major shift comes after the UK Treasury amended the Financial Services and Markets Act, allowing crypto-asset service providers to offer staking services to individuals and businesses within the United Kingdom. Impact of Regulatory...

Continue Reading
ASDS Annual Conference: Elevating Dermatology Education for 2025

Updated Category News Views 196

Registration Now Open for 2025 ASDS Annual Conference The American Society for Dermatologic Surgery (ASDS) has announced the opening of registration for its highly anticipated annual meeting. This prestigious event gathers dermatologists and their staff for a four-day immersive experience aimed at improving skills and knowledge in dermatologic surgery. The conference will...

Continue Reading
Revolutionizing Order Management with OMS+ Cloud Solution

Updated Category News Views 212

DataXstream Unveils OMS+ Cloud Solution for Enhanced Order Management DataXstream LLC has rolled out its latest innovation, the OMS+ Cloud specifically designed for SAP S/4HANA Cloud Public Edition, aiming to transform how businesses manage their sales and order processes. Transforming Sales and Order Processes For more than a decade, OMS+ has been at the forefront of...

Continue Reading
Innovative Paper Towel Stand Redefines Hygiene and Convenience

Updated Category News Views 170

Revolutionary Design for Paper Towel Dispensing In a world where hygiene is paramount, a visionary inventor from Oakgrove has developed an innovative solution known as the Adjustable Paper Towel Stand. This unique accessory is designed to dispense paper towels one at a time, effectively minimizing contact with the entire roll, which can often lead to contamination and...

Continue Reading